SCHEMBL25801850

SCHEMBL25801850

CCCc1ccc(CCc2noc(CC(C(=O)OC(C)(C)C)P(C)(=O)OCC)n2)cc1

nearest known ligand 0.34

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.33
PSMB5 P28074 5/20 0.31
KMT2A Q03164 2/20 0.31
POLB P06746 2/20 0.31
ADRB2 P07550 2/20 0.31
HPGD P15428 2/20 0.31
RAB9A P51151 2/20 0.31
NPSR1 Q6W5P4 2/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
PSMB8 P28062 1/20 0.31
S1PR1 P21453 1/20 0.30
S1PR3 Q99500 1/20 0.30
SRC P12931 2/20 0.30
NPC1 O15118 1/20 0.30
MAPT P10636 1/20 0.30
TDP1 Q9NUW8 1/20 0.30
MEN1 O00255 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25801881 0.94 L3MBTL1 (0.33) L3MBTL1KMT2ARAB9ASMN1; SMN2S1PR1
SCHEMBL25801972 0.94 MEN1 (0.35) L3MBTL1PSMB5KMT2APOLBADRB2
SCHEMBL25801750 0.93 TRPA1 (0.37) SMN1; SMN2MAPT
SCHEMBL23588069 0.91 L3MBTL1 (0.33) L3MBTL1PSMB5KMT2APOLBADRB2
SCHEMBL25801790 0.88 MEN1 (0.34) L3MBTL1KMT2ASRCMEN1
SCHEMBL25801813 0.87 SRC (0.33) KMT2AS1PR1S1PR3SRCMEN1
SCHEMBL25801838 0.87 SIRT2 (0.33) SMN1; SMN2SRCMAPT
SCHEMBL25801774 0.86 KMT2A (0.36) KMT2AHPGDRAB9ASMN1; SMN2SRC
SCHEMBL23588272 0.86 L3MBTL1 (0.33) L3MBTL1KMT2ARAB9ASMN1; SMN2S1PR1
SCHEMBL25801926 0.85 SRC (0.34) SRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230219907-A1 CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES SITRYX THERAPEUTICS LIMITED (GB) 2023-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219907-A1 CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES CPA2, RO60, C5AR1 L3MBTL1 3425/4885PSMB5 1688/4885KMT2A 3125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.